Discover an informative webinar discussing digital biomarkers in neuropsychiatric trials, leveraging an artificial intelligence (AI)-driven platform for enhanced treatment outcomes. Drugs for psychiatric conditions suffer some of the lowest approval rates when compared to other major therapeutic areas. Underlying factors can include complex and poorly understood etiology, which are heterogeneous in presentation, and underlying pathophysiology. Additionally, traditional clinical studies fail to objectively assess cognitive function as part of patient eligibility criteria or stratify patients according to the presence or degree of cognitive impairment. Cognitive function assessments and electroencephalogram (EEG) enable the measurement of pharmacodynamic endpoints in early-stage, translational psychiatric studies, however many studies do not leverage these tools today.
Attendees will learn about an AI-based, multi-domain digital biomarker platform to enable better, faster decision-making in neurology and neuropsychiatry clinical trials and patient care. The novel platform enables decentralized trials and is already used in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.
Designed to provide an industry-wide standard for real-world measurements of disease progression, the platform captures large amounts of real-world, clinical data repeated over time. The data is collected across multiple behavioral and physiological domains in the patient’s home using an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
Join this webinar to learn how to leverage neuroassessment platforms to advance novel therapeutics focused on neuropsychiatric conditions.
Dr. Snezana Milanovic, MD, MSc, Senior Director, Translational Medicine and Early Development, Sumitomo Pharma America
Snezana Milanovic, MD, MSc, serves as the Senior Director of Translational Medicine and Early Development at Sumitomo Pharma America, Inc. As a physician scientist and psychiatrist, she specializes in drug development for psychosis and mood disorders, with a keen interest in utilizing neuroplasticity-based biomarker tools such as EEG and cognitive tasks. Her academic journey includes faculty positions and program developments at Harvard and Boston Universities, along with residency and fellowship training at Yale and Harvard Universities. Additionally, she has held postdoctoral positions at the Max Planck Institute of Experimental Medicine, Central Institute for Mental Health (part of the German Center for Psychiatry and Heidelberg Mannheim Health & Life Science Alliance), and Stony Brook University, NY. Snezana obtained her MD and MSc degrees from the University of Belgrade, Serbia.
Alison Buick, PhD, Head of Global Business Development, Cumulus Neuroscience
Alison Buick, PhD, is the Global Head of Business Development at Cumulus Neuroscience. Having spent over six years at the company, previously directing clinical operations, Alison has deep knowledge of the Cumulus Neuroassessment Platform, understanding and insight into biopharma needs and delivery of effective end-to-end deployment in clinical trials.
Prior to joining Cumulus in 2017, Alison’s academic research (PhD and post-doctoral positions) in the UK, Ireland and Canada focused on neurophysiological interventions and medical devices for remote use, in disease areas spanning CNS, cardiovascular and oncology. With her background leading multi-site clinical operations, together with a successful academic track record in grant applications and publications, Alison’s current focus is on building strategic partnerships with biopharma and academic institutions to drive the adoption of innovative digital technologies to accelerate and enrich clinical trials.
Who Should Attend?
This webinar will appeal to professionals focused on diseases in the CNS space in the following fields:
- Biopharma clinical operations
- Clinical R&D
- Medical affairs
What You Will Learn
Attendees will gain insights into:
- How digital biomarkers have the potential to transform neuropsychiatry, enabling personalized treatment
- The power of longitudinal EEG data synchronized with behavioural assessment data
- How EEG data can accelerate neuropsychiatric clinical studies, saving time and budget
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.